Alzheimer's Drug Trials Keep Failing - It May Be Because We Don't Understand the Disease

(Inside Science) -- About a year ago, patients in a clinical trial of a Merck Alzheimer’s drug called Verubecestat received a phone call from their memory clinics. 

“Stop taking the pills and return those left to the clinic immediately,” they were told. “The trial has been cancelled.” 

My wife and about 1,500 Alzheimer’s patients around the world returned the containers of little blue pills back to their trial physicians. 

A statistical analysis of the first three years of the study showed there was no chance the drug would work. The test was costing hundreds of millions of dollars with no hope it would ever help patients or come to market. Another promising anti-Alzheimer’s drug had failed. 

>>>>>>